In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis is one such adverse effect that results in ulceration in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of developing oral mucositis with mean incidence of 80-100%.

It is estimated that 89.0%-100.0% of the population undergoing head and neck chemotherapy will develop oral mucositis. In addition there are >4M stage 3-4 cancer patients worldwide (>1m in U.S.) that are receiving high doses of CT or a combination of CT/RT that develop OM 1.0%-53.0% of the time.

The current status of Oral mucositis (OM) treatment includes basic oral care, cryotherapy, topical rinses such as lidocaine and carbomer and palifermin, and a growth factor. None of these products have been completely successful in treating OM and a high unmet medical need exists.

DelveInsight report on Oral Mucositis gives comparative study of drugs under development. The report provides assessment of AG-013 pipeline drug by ActogeniX NV (Intrexon) which is in Phase II/III. In addition to this, the report imparts information on several other drugs as well, among which 6 are in phase II, 3 in phase I, 3 in pre – clinical and 1 in discovery phase.


Key highlights of the report

  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

The Oral Mucositis-Pipeline Insights, 2015 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Oral Mucositis-Pipeline Insights helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Oral Mucositis-Pipeline Insight Report, email at

About Us

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.